Brett Leifson, APRN
Psychiatric/Mental Health · Scottsdale, AZNPI 1003338518
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $78,975 of the $89,806 with a category attached, or 87.9%. AbbVie accounts for 94.1% of it on its own, with 30 other manufacturers making up the rest. Reporting peaked in 2023 at $36,261 and has fallen 53.2% since, to $16,981 in 2025. Among psychiatric/mental health clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 400 payments — averaging $224.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$85K
- Johnson & Johnson$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Axsome Therapeutics, Inc.$478
- Neurocrine Biosciences, Inc.$343
- Janssen Scientific Affairs, LLC$290
- plus $2K from 25 others
What the payments were for
- Speaking & faculty fees$78,97588%
- Travel & lodging$2,2513%
- Food & beverage$8,4729%
- Education$1080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 264 | $84,549 |
| Johnson & Johnson | 28 | $1,141 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 22 | $1,019 |
| Axsome Therapeutics, Inc. | 7 | $478 |
| Neurocrine Biosciences, Inc. | 5 | $343 |
| Janssen Scientific Affairs, LLC | 4 | $290 |
| Alkermes, Inc. | 5 | $269 |
| Ironshore Pharmaceuticals Inc. | 9 | $250 |
| Almatica Pharma LLC | 10 | $220 |
| Tris Pharma Inc | 5 | $164 |
| Otsuka America Pharmaceutical, Inc. | 3 | $137 |
| Teva Pharmaceuticals USA, Inc. | 2 | $129 |
| Idorsia Pharmaceuticals US Inc | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $96 |
| E.r. Squibb & Sons, L.L.C. | 1 | $92 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $59 |
| Corium, LLC | 4 | $58 |
| Boston Scientific | 2 | $52 |
| Indivior Inc. | 3 | $50 |
| Amgen | 2 | $39 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| Impulse Dynamics (USA) Inc. | 2 | $31 |
| Sunovion Pharmaceuticals Inc. | 2 | $28 |
| Nevro Corp. | 1 | $24 |
| Pfizer | 1 | $23 |
| AstraZeneca | 1 | $23 |
| Lundbeck LLC | 1 | $20 |
| Abbott | 1 | $19 |
| Exact Sciences | 1 | $15 |
| Clarus Therapeutics Inc. | 1 | $15 |
| Novartis | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$89,806 in reported general payments places this provider in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 114 | $171,323 |
| VraylarCariprazine Hcl | 57 | $90,788 |
| CaplytaLumateperone Tosylate | 16 | $24,925 |
| Bupropion XlBupropion Hcl | 35 | $1,021 |
| Buspirone Hcl | 34 | $909 |
| Oxcarbazepine | 26 | $782 |
| Escitalopram Oxalate | 79 | $756 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $645 |
| Aripiprazole | 28 | $636 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 13 | $600 |
| Duloxetine Hcl | 25 | $567 |
| Trazodone Hcl | 63 | $505 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 16 | $400 |
| Bupropion Hcl SrBupropion Hcl | 11 | $380 |
| Quetiapine Fumarate | 20 | $351 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $1,141 | $171,323114 claims |
| AbbVieVraylar | $84,549 | $90,78857 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $1,019 | $24,92516 claims |
| Almatica Pharma LLCSertraline Hcl | $220 | $16019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,230 psychiatric/mental health providers in Arizona.
Other psychiatric/mental health in Scottsdale
- Bryan LazaroScottsdale$61K
- Chyllia DixonScottsdale$18K
- Denise DrakeScottsdale$7K
- Susan BowenScottsdale$6K
- Elizabeth ElliottPhoenix$363K
- Diane StrickerGilbert$281K
- Russell HorningPhoenix$254K
- Stacy UnderwoodMesa$252K
- Claire ReecePhoenix$88K
- Luis FongPhoenix$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.